Goldman Sachs has resumed its coverage of ArriVent Biopharma (AVBP, Financial), assigning a Buy rating and setting a price target of $33. The firm anticipates that the results from the Phase 3 FURVENT study will showcase significant clinical effectiveness, thereby strengthening the company's competitive position. This outlook reflects confidence in ArriVent Biopharma's potential to deliver strong performance in the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for ArriVent BioPharma Inc (AVBP, Financial) is $41.13 with a high estimate of $45.00 and a low estimate of $37.00. The average target implies an upside of 92.71% from the current price of $21.34. More detailed estimate data can be found on the ArriVent BioPharma Inc (AVBP) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, ArriVent BioPharma Inc's (AVBP, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
